ahlam1399
07-27-2016, 04:02 PM
GSK chases next biotech asthma drug with $230 million J&J deal
LONDON (Reuters) - GlaxoSmithKline has bought global rights to an experimental drug from Johnson & Johnson for up to 175 million pounds ($230 million), raising its bet on a new generation of biotech medicines for severe asthma.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=_KghM-BhoQk:-0LkLrvW_zc:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=_KghM-BhoQk:-0LkLrvW_zc:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=_KghM-BhoQk:-0LkLrvW_zc:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=_KghM-BhoQk:-0LkLrvW_zc:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=_KghM-BhoQk:-0LkLrvW_zc:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/_KghM-BhoQk
LONDON (Reuters) - GlaxoSmithKline has bought global rights to an experimental drug from Johnson & Johnson for up to 175 million pounds ($230 million), raising its bet on a new generation of biotech medicines for severe asthma.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=_KghM-BhoQk:-0LkLrvW_zc:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=_KghM-BhoQk:-0LkLrvW_zc:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=_KghM-BhoQk:-0LkLrvW_zc:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=_KghM-BhoQk:-0LkLrvW_zc:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=_KghM-BhoQk:-0LkLrvW_zc:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/_KghM-BhoQk